To hear about similar clinical trials, please enter your email below
Trial Title:
Evaluation of a Novel Technique for the Discovery of New, Tumor-specific Targets for the Deployment of Innovative Immunotherapeutics Against Cancer.
NCT ID:
NCT06629233
Condition:
Estrogen Receptor Positive Breast Cancer
Study type:
Interventional
Study phase:
N/A
Overall status:
Enrolling by invitation
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Other
Masking:
None (Open Label)
Intervention:
Intervention type:
Procedure
Intervention name:
Tumor resection
Description:
As the standard of care, estrogen receptor-positive breast tumors are surgically
resected. From these resected tumors, small samples of both cancer tissue and healthy
surrounding tissue will be analyzed using our patented Tn-Miner workflow to discover
novel tumor-specific epitopes.
Arm group label:
Standard of care tumor resection
Summary:
The goal of this interventional, prospective research on human bodily material is to
discover new, cancer-specific molecular structures (i.e. glycopeptides) within surgically
removed, estrogen receptor positive breast cancer tumors.
The main goal it aims to achieve is:
To discover tumor-specific targets, that allow the use of very potent immunotherapeutic
drugs as treatment for solid tumors, such as estrogen receptor positive breast cancer.
These new targets are very specific for cancer cells, meaning that virtually no healthy
cells should be attacked by the treatment, resulting in less side effects.
Participants will undergo standard of care treatment, comprising surgical removal of the
breast tumor. Part of these tissues will be used for this clinical research.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Female
- Minimally 18 years old
- Diagnosed with estrogen-receptor positive breast cancer
- This must be a primary tumor
Exclusion Criteria:
- Male
- Younger than 18 years old
- Previous history of other tumors
Gender:
Female
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
AZ Maria Middelares
Address:
City:
Ghent
Zip:
9000
Country:
Belgium
Facility:
Name:
University Hospital Ghent
Address:
City:
Ghent
Zip:
9000
Country:
Belgium
Start date:
September 25, 2024
Completion date:
April 14, 2025
Lead sponsor:
Agency:
University Ghent
Agency class:
Other
Collaborator:
Agency:
University Hospital, Ghent
Agency class:
Other
Collaborator:
Agency:
Algemeen Ziekenhuis Maria Middelares
Agency class:
Other
Source:
University Ghent
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06629233
